River Vision Overview

  • Founded
  • 2011

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $475M

River Vision General Information


Developer of protein therapies designed for the treatment of Graves' Orbitopathy. The company's protein therapies include a human monoclonal antibody Teprotumumab, is a fully human mAb inhibitor of insulin-like growth factor type 1 receptor (IGF-1R) used for the treatment of active phase Graves Orbitopathy (GO), enabling users treat patients with tissue proliferation and excess production of extracellular matrix.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • One Rockefeller Plaza
  • Suite 1204
  • New York, NY 10020
  • United States
+1 (212) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

River Vision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 08-May-2017 $475M 000.00 00000 Completed Product Development
5. Early Stage VC (Series B) 01-May-2017 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 21-Jan-2016 000 000.00 000.00 Completed Startup
3. Early Stage VC (Series A) 02-Feb-2015 00.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 07-Jan-2014 $6M $17M 000.00 Completed Startup
1. Early Stage VC (Series A) 10-Dec-2012 $11M $11M 000.00 Completed Startup
To view River Vision’s complete valuation and funding history, request access »

River Vision Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view River Vision’s complete cap table history, request access »

River Vision Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Lundbeckfonden BioCapital Venture Capital Minority 000 0000 000000 0
Narrow River Management Limited Partner Minority 000 0000 000000 0
SR One Venture Capital Minority 000 0000 000000 0
Vivo Capital Venture Capital Minority 000 0000 000000 0
To view River Vision’s complete investors history, request access »